New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

(Adnkronos) – Randomized Placebo-Controlled Study Published in Pain Management Evaluated the Preventive Efficacy of the Non-Drug Wearable As Early As After Two Weeks of Usage NETANYA, Israel and BRIDGEWATER, N.J., Sept. 12, 2023 /PRNewswire/ — Theranica, a neuromodulation therapeutics company, announced the results of a study recently published in Pain Management, suggesting the rapid impact of Nerivio, the first and only migraine neuroband, in reducing the number of migraine days. A previous study has already shown that using Nerivio every other day for 8 weeks reduces the mean number of migraine days per month by 4.0 days (compared to 1.3 days in the placebo group, p 

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *